Combination therapy of sustained release immune modulatory drug and PEGylation of islets in presence of hydrogel for treatment of type 1 diabetes mellitus
발표자
()
초록
내용
Though, normoglycemia and the reduction of many complications of type 1 diabetes are achieved through islet transplantation, the life long need of systemic immunosuppressive drug and immune rejection of graft after transplantation are common in islet transplantation. Here, in this study we report the single synchronous delivery of pegylated islet cells and prolonged and sustained rapamycin releasing microspheres (RMs) in presence of hydrogel in the subcutaneous space of mice resulted in long term functioning of the graft. Immunohistochemical analysis revealed the higher infiltration of immune cells inside the graft without pegylation and rapamycin. In addition, graft, graft associated tissue(GAT), spleen and peripheral lymph nodes(PLN) showed higher amount of CD40, CD80, CD86 and CCR7 activated dendritic cells and CD4+ and CD8+ t-cells in control group as compared to PEGylated islet transplanted group.